Skip to content
Homepage
Author:
Theriva Biologics, Inc.
Posted Date:
August 11, 2026
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
Theriva Biologics, Inc.
August 11, 2026
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Theriva Biologics, Inc.
August 6, 2026
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Theriva Biologics, Inc.
July 7, 2026
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
Theriva Biologics, Inc.
June 11, 2026
